Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidaseDouglas B Muchmore
Halozyme Therapeutics Inc, San Diego, California 92121, USA
J Diabetes Sci Technol 6:764-72. 2012
..Further studies of rHuPH20 in the take-home treatment setting are underway...
- The end point is just the beginning
Douglas Muchmore
Halozyme Therapeutics, Inc, San Diego, California 92121, USA
J Diabetes Sci Technol 5:1287-9. 2011
..An example would be "percentage of patients achieving A1C <7% without unacceptable hypoglycemia." The benefits and limitations of such an approach are discussed...
- Benefits of blinded continuous glucose monitoring during a randomized clinical trial
Douglas Muchmore
Halozyme Therapeutics, Inc, San Diego, California, USA
J Diabetes Sci Technol 5:676-80. 2011
..This study was designed to investigate the use of novel procedures to enhance data capture from blinded CGM...
- Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations
Douglas B Muchmore
Halozyme Therapeutics, Inc, San Diego, California, USA
J Diabetes Sci Technol 4:419-28. 2010
....
Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusionDaniel E Vaughn
Halozyme Therapeutics, Inc, San Diego, California 92121, USA
Endocr Pract 17:914-21. 2011
..To discuss clinical studies in which recombinant human hyaluronidase (rHuPH20) was used to increase insulin dispersion and accelerate its absorption...
- Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase
Marcus Hompesch
Profil Institute for Clinical Research, Chula Vista, California, USA
Diabetes Technol Ther 14:218-24. 2012
....
- Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase
Daniel E Vaughn
Halozyme Therapeutics, Inc, San Diego, California 92121, USA
Diabetes Technol Ther 11:345-52. 2009
..Indianapolis, IN) or regular human insulin (Humulin R; Eli Lilly and Co.) administered with or without (+/-) recombinant human hyaluronidase (rHuPH20)...
- Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase
Marcus Hompesch
Profil Institute for Clinical Research, Chula Vista, California, USA
Diabetes Care 34:666-8. 2011
..To compare the pharmacokinetics, pharmacodynamics, and safety of insulin lispro or regular human insulin (RHI) with or without recombinant human hyaluronidase (rHuPH20) administered before a standardized meal...
- Inhaled insulin for controlling blood glucose in patients with diabetes
Bernard L Silverman
Alkermes, Inc, Cambridge, MA, USA
Vasc Health Risk Manag 3:947-58. 2007
....
- Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers
Linda Morrow
Profil Institute for Clinical Research, Chula Vista, California, USA
Diabetes Technol Ther 13:1039-45. 2011
....
